The Pre-filled Syringes and Injectable Devices Conference 2022 is only 1 week away

LONDON - Jan. 6, 2022 - PRLog -- Access will be fully online meaning therefore limiting any risk from the omicron variant of Covid-19. This will allow more attendees to join from across the world without having to worry about rules and regulations at the time. The event will deliver the same fantastic content which you will be able to attend and access from the comfort of your computer screen whether you choose to do that from your home or office!

The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. This year's conference will explore the exciting advances in the combination product delivery space including insights into how the industry is adapting to the delayed EU MDR, takeaways from the global pandemic and a future outlook exploring how pharma, device developers and regulators can work together to encourage innovation.

As Europe's leading Pre-Filled Syringes Conference, in  2022 the event will bring together expertise from individuals in multiple disciplines in the field addressing key areas with recent developments in the industry including connectivity for drug delivery, insights into a fragile molecules and long acting injectables, parental delivery design  approaches and digitalization in device development.

Visit the website here: http://www.pre-filled-syringes.com/

Key reasons why individuals must attend include:

• Engage with industry leaders on the key takeaways from the pandemic and how this can be applied to future accelerated development
• Explore updates to drug device combination product design approaches putting the user first with industry case studies from big pharma
• Assess the current landscape of device delivery mechanisms and how industry can work together to promote innovation
• Understand the landscape of delivery for novel drug products, fragile molecules and long acting injectables in the interactive panel discussion

Featured Key Speakers:

• David Braun, Head of Connected Health and Medical Devices Business Solutions, Merck Group
• Louise Place, Director, Devices, GSK
• Jochen Zenker, Head of Laboratory Process Engineering, Device Development, Boehringer Ingelheim
• Joel Richard, Chief Development Officer, MedinCell
• Sachin Dubey, Head of Drug Product and Analytical Development, Ichnos Sciences
• Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
• Richard Simcock, Human Factors Scientist, CPD, Teva
• Michael Becker, Packaging Engineer, Launch + Transfer Operations, Boehringer Ingelheim Pharma GmbH & Co. KG
• Arabe Ahmed, Medicinal Technical Expert, BSI

For media enquiries contact Richard Jones on Tel: +44 (0)20 7827 6088 / Email:  rjones@smi-online.co.uk

--- ENDS –